StemCell Therapy

September 25, 2020

Albert Mitranihas been Chief Operating Officer, President and board member at Organicell Regenerative Medicine, Inc. since April 2018, and he also is the Chairman of the board, Chief Executive Officer, Secretary and Treasurer at Organicell Regenerative Medicine, Inc. alternate name Biotech Products since June 24, 2011.

Mr. Mitrani formerly was the Chief Executive Officer, President and Director of Analytical Stem Cell Corp. from April 2014 to May 2015. From February 2012 to March 2014, he was the Chief Executive Officer of Americell Trinidad and the President of ASCAAC LLC American Stem Cell from March 2011 to January 2013. Mr. Mitrani was the Chief Executive Officer of American Cellular Center in Quito Ecuador from 2009 through 2012.

In this 2,511 word interview, exclusively in the Wall Street Transcript, Mr. Mitrani explains why investors should look at buying stock in his publicly traded company.

For several years, we have been doing a lot of research in various areas, specifically around lung diseases, and have collected data, more specifically around lung reparation.

When COVID hit, we came to the realization that through all of our work and expertise around regenerative therapeutics for the lungs, that there could be a potential opportunity for us to make a big difference in the treatment of this virus, particularly for patients with more severe lung injury and illness.

This particular treatment developed from some core stem cell therapy applications.

And with this knowledge of stem cells, we transitioned out of autologous stem cells and began searching for a regenerative therapy that would be more consistent. Particularly, something that we would be able to commercialize with reproducible and consistent effects.

Autologous stem cell therapies utilized autologous stem cells derived from the patients own blood. When you isolate these cells, the stem cell quality varies from patient to patient. The health of the stem cell population is largely dependent upon the patients health status and underlying conditions.

In our search for a better therapeutic source of cells for regenerative therapies, we ultimately focused on perinatal tissue

However, one component of paracrine factors that we found to be most promising for regenerative therapies were cell-secreted nanoparticles called exosomes and extracellular vesicles.

This type of therapy no longer requires the use of stem cells or cells. Our ability to identify and isolate these perinatal-derived exosomes is what really changed the direction of our company.

Get all the details on this potentially life changing drug discovery by reading the entire 2,511 word interview with Mr. Mitrani, exclusively in the Wall Street Transcript.

View post:
Perinatal-Derived Exosomes are the Key to this Biotech's Treatment Therapies - The Wall Street Transcript

This entry was posted on September 28, 2020 at 4:54 pm and is filed under Stem Cell Therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |